Abstract: In accordance with the present invention, there are provided formulations of gamma secretase modulators (GSMs) which are suitable for oral delivery and have improved transport properties relative to prior art formulations thereof. Also provided are methods for the preparation of such improved formulations and uses thereof for the delivery of GSMs to subjects in need thereof.
Type:
Application
Filed:
August 9, 2013
Publication date:
February 12, 2015
Applicant:
Neurogenetic Pharmaceuticals, Inc.
Inventors:
William T. COMER, Maria Z. KOUNNAS, Bryan M. KNOX, Nathan S. BARKSDALE
Abstract: In accordance with the present invention, it has been discovered that compounds which modulate the ?-secretase enzyme to make more of the shorter, less toxic and less aggregation-prone A? peptides (such as A?37 and A?38), while making less of the longer and more toxic and aggregation-prone AB peptides (such as AB40 and AB42) are useful as gamma-secretase modulators. In addition, these GSM compounds have further been discovered to have the selective property of modulating the formation of various AB peptides, while not inhibiting the overall activity of the ?-secretase enzyme. Thus, such compounds do not impede other critical functions of the ?-secretase enzyme, such as generating fragments from Notch that appear to control gene expression and cell differentiation. Therefore, in accordance with the present invention, there are provided screening assays useful for determining whether test compounds have GSM activity; accordingly, invention assays facilitate the identification of new gamma-secretase modulators.
Type:
Grant
Filed:
November 8, 2010
Date of Patent:
October 28, 2014
Assignee:
Neurogenetic Pharmaceuticals, Inc.
Inventors:
Maria Z. Kounnas, Elizabeth J. Ackermann, Kenneth A. Stauderman, Gonul Velicelebi, Steve Wagner
Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
Type:
Grant
Filed:
September 3, 2010
Date of Patent:
February 21, 2012
Assignee:
Neurogenetic Pharmaceuticals, Inc.
Inventors:
Soan Cheng, Daniel D Comer, Long Mao, Guity P Balow, David Pleynet
Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
Type:
Grant
Filed:
August 23, 2010
Date of Patent:
September 13, 2011
Assignee:
Neurogenetic Pharmaceuticals, Inc.
Inventors:
Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
Type:
Grant
Filed:
June 19, 2007
Date of Patent:
September 21, 2010
Assignee:
Neurogenetic Pharmaceuticals, Inc.
Inventors:
Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
Type:
Grant
Filed:
July 17, 2007
Date of Patent:
August 24, 2010
Assignee:
Neurogenetic Pharmaceuticals, Inc.
Inventors:
Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet